Hal Mintz, the manager of Sabby Capital, believes StemCells Inc (NASDAQ:STEM) is a good investment and has opened a position for his fund. According a recent filing with the Securities and Exchange Commission, Sabby Capital has acquired 6.85 million shares, which account for approximately 9.98% of the total number of shares outstanding.
Ken Griffin, the billionaire hedge fund manager, also likes StemCells Inc (NASDAQ:STEM) and has increased his fund’s stake in the company by 133% during the first quarter of this year. In its latest 13F filing, Citadel has reported ownership of approximately 25,500 shares. David E. Shaw, on the other hand, has chosen to reduce his fund’s investment in this stock by a half to 21,600 shares. Joseph Edelman, the manager of Perceptive Advisors, is also keeping tabs on StemCells Inc (NASDAQ:STEM) having made no changes to their investment during the first quarter. Perceptive Advisors holds a little more than 271,000 shares.
Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) is another new addition to the equity portfolio of Sabby Capital. Mintz has bought approximately 858,500 shares, which gives him and Sabby Capital control over 9.99% of the total number of shares outstanding.
None of the hedge funds that we track currently holds a position in Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI). For the first quarter of 2014, the company posted revenues of $6.83 million, up 23% year-over-year, and earnings per share (EPS) of $0.13. So far this year the stock has been trending upwards and has advanced 52% to a current price of $5.31 per share. This gives the company a market cap of $40.4 million. The stock is traded at a trailing Price to Earnings of 3.xx, which is significantly lower than the industry average of 21.60.
Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) recently announced an agreement with a dedicated institutional investor to acquire $5 million worth of registered securities. The proceedings are to be used by Skystar for corporate purposes and research and development.